Managing Gout in Women: Current Perspectives

Overview

Journal J Inflamm Res

Publisher Dove Medical Press

Date 2022 Mar 10

PMID 35264868

Authors

Aakash V Patel

Angelo L Gaffo

Affiliations

Soon will be listed here.

Abstract

Gout is a common inflammatory arthritis that tends to affect significantly more men than women. However, female gout patients are more likely to have comorbidities such as hypertension, diabetes mellitus, and renal dysfunction. Furthermore, they experience a greater disease burden due to gout than males. While nonbiological causes may possibly contribute to this sex discrepancy in burden, this raises questions regarding whether current gout pharmacotherapies are as efficacious in females as they are in males. In this review, we examine how the clinical profile of female gout patients differs from male patients; we then survey the literature for data on outcomes for female gout patients treated with urate-lowering therapies for chronic management of gout as well as commonly used agents for acute flares. We also discuss considerations for managing gout in women during pregnancy and lactation.

Citing Articles

Unclosing Premature Mortality Gap Among Patients With Gout in the US General Population, Independent of Serum Urate and Atherosclerotic Cardiovascular Risk Factors.

McCormick N, Lin K, Yokose C, Lu N, Zhang Y, Choi H Arthritis Care Res (Hoboken). 2024; 76(5):691-702.

PMID: 38191784 PMC: 11039387. DOI: 10.1002/acr.25292.

A dose-escalation study of HP501, a highly selective URAT1 inhibitor, in male Chinese patients with hyperuricemia.

Ding R, Deng X, Chen L, Zhen Y, Li X, Xiong T Sci Rep. 2023; 13(1):22190.

PMID: 38092845 PMC: 10719327. DOI: 10.1038/s41598-023-49052-x.

A Phase I Study to Evaluate the Pharmacokinetic Drug‒Drug Interaction of HP501, Febuxostat, and Colchicine in Male Chinese Patients with Hyperuricemia.

Ding R, Chen L, Li X, Xiong T, Chen H, Hu X Clin Drug Investig. 2023; 43(6):401-411.

PMID: 37248357 DOI: 10.1007/s40261-023-01274-7.

References

Foody J, Turpin R, Tidwell B, Lawrence D, Schulman K . Major Cardiovascular Events in Patients with Gout and Associated Cardiovascular Disease or Heart Failure and Chronic Kidney Disease Initiating a Xanthine Oxidase Inhibitor. Am Health Drug Benefits. 2017; 10(8):393-401. PMC: 5726059. View

Narang R, Topless R, Cadzow M, Gamble G, Stamp L, Merriman T . Interactions between serum urate-associated genetic variants and sex on gout risk: analysis of the UK Biobank. Arthritis Res Ther. 2019; 21(1):13. PMC: 6327586. DOI: 10.1186/s13075-018-1787-5. View

Vogt B . Urate oxidase (rasburicase) for treatment of severe tophaceous gout. Nephrol Dial Transplant. 2005; 20(2):431-3. DOI: 10.1093/ndt/gfh629. View

Rubin B, Burton R, Navarra S, Antigua J, Londono J, Pryhuber K . Efficacy and safety profile of treatment with etoricoxib 120 mg once daily compared with indomethacin 50 mg three times daily in acute gout: a randomized controlled trial. Arthritis Rheum. 2004; 50(2):598-606. DOI: 10.1002/art.20007. View

FitzGerald J, Dalbeth N, Mikuls T, Brignardello-Petersen R, Guyatt G, Abeles A . 2020 American College of Rheumatology Guideline for the Management of Gout. Arthritis Rheumatol. 2020; 72(6):879-895. DOI: 10.1002/art.41247. View

Simmonds H, Cameron J, Goldsmith D, Fairbanks L, Venkat Raman G . Familial juvenile hyperuricaemic nephropathy is not such a rare genetic metabolic purine disease in Britain. Nucleosides Nucleotides Nucleic Acids. 2006; 25(9-11):1071-5. DOI: 10.1080/15257770600891028. View

Yoo H, Lee S, Chae H, Park S, Lee Y, Yoo W . Prevalence of insulin resistance and metabolic syndrome in patients with gouty arthritis. Rheumatol Int. 2010; 31(4):485-91. DOI: 10.1007/s00296-009-1304-x. View

Sundy J, Baraf H, Yood R, Edwards N, Gutierrez-Urena S, Treadwell E . Efficacy and tolerability of pegloticase for the treatment of chronic gout in patients refractory to conventional treatment: two randomized controlled trials. JAMA. 2011; 306(7):711-20. DOI: 10.1001/jama.2011.1169. View

Becker M, Schumacher H, Espinoza L, Wells A, Macdonald P, Lloyd E . The urate-lowering efficacy and safety of febuxostat in the treatment of the hyperuricemia of gout: the CONFIRMS trial. Arthritis Res Ther. 2010; 12(2):R63. PMC: 2888216. DOI: 10.1186/ar2978. View

10.

Kuo C, Grainge M, Mallen C, Zhang W, Doherty M . Rising burden of gout in the UK but continuing suboptimal management: a nationwide population study. Ann Rheum Dis. 2014; 74(4):661-7. PMC: 4392307. DOI: 10.1136/annrheumdis-2013-204463. View

11.

Perez-Ruiz F, Dalbeth N . Combination urate-lowering therapy in the treatment of gout: What is the evidence?. Semin Arthritis Rheum. 2018; 48(4):658-668. DOI: 10.1016/j.semarthrit.2018.06.004. View

12.

Lhotta K, Gehringer A, Jennings P, Kronenberg F, Brezinka C, Andersone I . Familial juvenile hyperuricemic nephropathy: report on a new mutation and a pregnancy. Clin Nephrol. 2009; 71(1):80-3. DOI: 10.5414/cnp71080. View

13.

Roman Y, Tiirikainen M, Prom-Wormley E . The prevalence of the gout-associated polymorphism rs2231142 G>T in ABCG2 in a pregnant female Filipino cohort. Clin Rheumatol. 2020; 39(8):2387-2392. DOI: 10.1007/s10067-020-04994-9. View

14.

Pui K, Gow P, Dalbeth N . Efficacy and tolerability of probenecid as urate-lowering therapy in gout; clinical experience in high-prevalence population. J Rheumatol. 2013; 40(6):872-6. DOI: 10.3899/jrheum.121301. View

15.

Becker M, Schumacher Jr H, Wortmann R, MacDonald P, Eustace D, Palo W . Febuxostat compared with allopurinol in patients with hyperuricemia and gout. N Engl J Med. 2005; 353(23):2450-61. DOI: 10.1056/NEJMoa050373. View

16.

Mackenzie I, Ford I, Nuki G, Hallas J, Hawkey C, Webster J . Long-term cardiovascular safety of febuxostat compared with allopurinol in patients with gout (FAST): a multicentre, prospective, randomised, open-label, non-inferiority trial. Lancet. 2020; 396(10264):1745-1757. DOI: 10.1016/S0140-6736(20)32234-0. View

17.

Wipfler-Freibmuth E, Dejaco C, Duftner C, Gaugg M, Kriessmayr-Lungkofler M, Schirmer M . Urate oxidase (rasburicase) for treatment of severe acute gout: a case report. Clin Exp Rheumatol. 2009; 27(4):658-60. View

18.

Singh J, Gaffo A . Gout epidemiology and comorbidities. Semin Arthritis Rheum. 2020; 50(3S):S11-S16. DOI: 10.1016/j.semarthrit.2020.04.008. View

19.

McCarty D, HOLLANDER J . Identification of urate crystals in gouty synovial fluid. Ann Intern Med. 1961; 54:452-60. DOI: 10.7326/0003-4819-54-3-452. View

20.

Thueringer J, Doll N, Gertner E . Anakinra for the treatment of acute severe gout in critically ill patients. Semin Arthritis Rheum. 2015; 45(1):81-5. DOI: 10.1016/j.semarthrit.2015.02.006. View